Physician profile
Maxim Mitchell
NPI 1194175968
$8,046.90
in general payments reported to CMS, 2019-2025
42 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $1,462 · 2021: $1,340 · 2022: $1,633 · 2023: $1,489 · 2024: $724 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,494.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,339.93 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $839.77 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $832.27 | 2020-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals Lp | $766.74 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $598.78 | 2021-2025 | |
| Abbvie INC. | $421.10 | 2021-2025 | |
| Glaxosmithkline, LLC. | $344.42 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Daiichi Sankyo INC. | $236.20 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.77 | 2020-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Exact Sciences Corporation | $194.57 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amarin Pharma, INC. | $187.11 | 2019-2021 | |
| Astellas Pharma US INC | $174.01 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $137.06 | 2022-2025 | Gardasil 9, Vaxelis, Vaqta |
| Abbott Laboratories | $128.21 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $127.82 | 2022-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxim Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.